FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
This article was originally published in The Tan Sheet
Executive Summary
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics